Business Description
Cognition Therapeutics is a New York-based drug development company focused on treating brain and eye diseases that worsen with age. Its primary drug, CT1812, is taken by mouth and works by targeting a specific protein complex in the body, and is currently being tested in multiple Phase 2 trials for conditions including Alzheimer's disease, a form of vision loss called geographic atrophy, and Lewy body dementia. The company has been working in this field since its founding in 2007.
